GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Float Percentage Of Total Shares Outstanding

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Float Percentage Of Total Shares Outstanding : 99.92% (As of May. 03, 2024)


View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, HTG Molecular Diagnostics's float shares is 2.21 Mil. HTG Molecular Diagnostics's total shares outstanding is 2.21 Mil. HTG Molecular Diagnostics's float percentage of total shares outstanding is 99.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, HTG Molecular Diagnostics's Insider Ownership is 22.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, HTG Molecular Diagnostics's Institutional Ownership is 0.01%.


HTG Molecular Diagnostics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

HTG Molecular Diagnostics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.21/2.21
=99.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.
Executives
Stephen Barat officer: Senior VP of Therapeutics C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc. 10 percent owner 1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy director
Byron Lawson officer: SVP/Chief Commercial Officer C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson director, officer: President & CEO
Laurence W Lytton 10 percent owner 467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski officer: VP of Accounting and Reporting C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans officer: VP, Finance & Admin. & CFO 3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen 10 percent owner HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison director